Clinical meaning
Chronic kidney disease–mineral and bone disorder (CKD-MBD) develops as declining GFR impairs phosphate excretion and 1,25-dihydroxyvitamin D (calcitriol) synthesis. Hyperphosphatemia begins in CKD stage 3 (eGFR <60) as phosphate excretion capacity is overwhelmed. Elevated phosphate directly stimulates parathyroid hormone (PTH) secretion and FGF-23 production, while reduced calcitriol synthesis decreases intestinal calcium absorption, further stimulating PTH (secondary hyperparathyroidism). Chronic PTH elevation causes renal osteodystrophy: high-turnover bone disease (osteitis fibrosa cystica from excessive osteoclastic resorption), low-turnover disease (adynamic bone disease from over-suppression of PTH), and mixed uremic osteodystrophy. Elevated calcium-phosphate product (Ca × P >55) promotes metastatic vascular calcification, increasing cardiovascular mortality — cardiovascular disease is the leading cause of death in CKD/ESRD, and vascular calcification is a major contributor. Phosphate binder selection: calcium-based binders (calcium carbonate, calcium acetate) bind dietary phosphate in the GI tract, preventing absorption; however, excessive calcium loading promotes vascular calcification — non-calcium binders (sevelamer, lanthanum) are preferred in CKD stages 4-5 and dialysis patients. Active vitamin D (calcitriol) or analogs (paricalcitol, doxercalciferol) supplement deficient 1,25(OH)2D and suppress PTH secretion, but require calcium and phosphate monitoring to prevent...